BetterLife launches new corporate website

VANCOUVER, British Columbia, Feb. 28, 2022 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR/ OTCQB: BETRF/ FRA: NPAU), an emerging biotechnology company focused on the development and commercialization of 2n/a-generation of non-hallucinogenic psychedelic analogues for the treatment of neuropsychological disorders, is pleased to announce the launch of its new website. The company’s newly designed website better showcases BetterLife’s mission to develop innovative new medicines to treat mental health disorders, such as depression and anxiety. The new website can be accessed at https://abetterlifepharma.com/.

“Over the past year, our team has made significant progress in the development of our lead compounds, BETR-001 and BETR-002. We have obtained strong preclinical data to position BETR-001 as a leading candidate for the potential treatment of certain mental health disorders affecting millions of people worldwide. The non-hallucinogenic properties of BETR-001, combined with our proprietary uncontrolled (scheduled) manufacturing process, enable faster development and treatment of millions more patients. With recent guidance from the FDA, we continue to generate additional data to complete our Investigational New Drug (IND) application to be submitted in the second half of this year,” said BetterLife Chief Executive Dr. Ahmad Doroudian.

About BetterLife Pharma

BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on the development and commercialization of two compounds, BETR-001 and BETR-002, to treat neuropsychiatric and neurological disorders.

BETR-001 (formerly TD-0148A), which is in preclinical and IND-enabling studies, is a non-hallucinogenic, uncontrolled LSD derivative in development and is unique in that it does not is not regulated and can therefore be self-administered. BetterLife’s synthetic patent for BETR-001 eliminates regulatory hurdles and its patent pending composition and method of use covers the treatment of depression, cluster headaches, post-traumatic stress disorder and other neuropsychiatric and neurological disorders.

BETR-002 (formerly TD-010), which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient in magnolia bark. BetterLife’s method of use and formulations patent pending covers the treatment of anxiety-related disorders, including benzodiazepine addiction.

BetterLife also has a drug candidate for the treatment of viral infections such as COVID-19 and is researching strategic alternatives for further development.

For more information, please visit https://abetterlifepharma.com/.

Contact details

David Meles, Investor Relations Manager
Email: [email protected]
Phone: 1-778-887-1928

Caution Regarding Forward-Looking Statements

No stock exchange has reviewed or accepts responsibility for the adequacy or accuracy of the contents of this press release. This press release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by words such as “will”, “may”, “should”, “anticipate”, “expect” and similar expressions. All statements, other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include failure to meet the conditions of the relevant stock exchange(s) and other risks detailed from time to time in documents filed by the Company with securities regulations. Readers are cautioned that the assumptions used in preparing any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those anticipated due to numerous known and unknown risks, uncertainties and other factors, many of which are beyond the Company’s control. Readers are cautioned not to place undue reliance on forward-looking information. Such information, although considered reasonable by management at the time it was prepared, may prove to be incorrect and actual results may differ materially from those anticipated. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement. The forward-looking statements contained in this press release are made as of the date of this press release and the Company will publicly update or revise any of the forward-looking statements included as expressly required by applicable law.

Comments are closed.